RGD Reference Report - Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN.

Authors: Branca, M  Ciotti, M  Giorgi, C  Santini, D  Di Bonito, L  Costa, S  Benedetto, A  Bonifacio, D  Di Bonito, P  Paba, P  Accardi, L  Syrjanen, S  Favalli, C  Syrjanen, K  Syrjänen, K 
Citation: Branca M, etal., Anticancer Res. 2006 Mar-Apr;26(2B):1543-56.
RGD ID: 2290402
Pubmed: PMID:16619570   (View Abstract at PubMed)

OBJECTIVE: Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are important regulators of cancer invasion and metastasis. Their associations to high-risk (HR) human papillomavirus (HPV) in cervical intra-epithelial neoplasia (CIN) and cervical cancer (CC) are unexplored and their prognostic significance in CC remains controversial. MATERIALS AND METHODS: As part of our HPV-PathogenISS study, a series of 150 CCs and 152 CIN lesions were examined using immunohistochemical (IHC) staining for MMP-2 and TIMP-2 and tested for HPV using PCR with 3 primer sets (MY09/11, GP5+/GP6+, SPF). Follow-up data were available from all squamous cell carcinoma patients and 67 CIN lesions had been monitored with serial PCR for HPV after cone treatment. RESULTS: MMP-2 increased with the grade of CIN, with major up-regulation upon transition to invasive cancer (OR 20.78) (95%CI 7.16-60.23) (p=0.0001). TIMP-2 retained its normal expression until CIN3, with dramatic down-regulation in invasive disease (p=0.0001 for trend). Thus, the MMP2:TIMP-2 ratio increased with progressive CIN, exceeding the value 1.0 only in invasive disease. Both MMP-2 and TIMP-2 are highly specific (TIMP-2; 100%) discriminators of CIN with 100% positive predictive value (TIMP-2), but suffer from low sensitivity and negative predictive value. Neither MMP-2 nor TIMP-2 showed any significant association with HR HPV or virus persistence/clearance. TIMP-2 (but not MMP-2) was a significant predictor of survival in univariate (Kaplan-Meier) analysis (p=0.007), but lost its significance in multivariate (Cox) analysis. CONCLUSION: The activities of MMP-2 and TIMP-2 in cervical carcinogenesis seem to be unrelated to HR-HPV The inverse MMP-2:TIMP-2 ratio is a sign of poor prognosis. A combination of a TIMP-2 assay with another test showing high SE and high NPV (e.g., HCII for HPV) should provide a potential screening tool capable of accurate detection of CIN.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
cervical squamous cell carcinoma  IEP 2290402protein:decreased expression:uterine cervixRGD 
cervical squamous cell carcinoma  ISOTIMP2 (Homo sapiens)2290402; 2290402protein:decreased expression:uterine cervixRGD 
cervix uteri carcinoma in situ disease_progressionIEP 2290402protein:increased expression:uterine cervixRGD 
cervix uteri carcinoma in situ disease_progressionISOMMP2 (Homo sapiens)2290402; 2290402protein:increased expression:uterine cervixRGD 
Uterine Cervical Neoplasms  IEP 2290402protein:increased expression:uterine cervixRGD 
Uterine Cervical Neoplasms  ISOMMP2 (Homo sapiens)2290402; 2290402protein:increased expression:uterine cervixRGD 

Objects Annotated

Genes (Rattus norvegicus)
Mmp2  (matrix metallopeptidase 2)
Timp2  (TIMP metallopeptidase inhibitor 2)

Genes (Mus musculus)
Mmp2  (matrix metallopeptidase 2)
Timp2  (tissue inhibitor of metalloproteinase 2)

Genes (Homo sapiens)
MMP2  (matrix metallopeptidase 2)
TIMP2  (TIMP metallopeptidase inhibitor 2)


Additional Information